Verified ComparisonLast updated: 20 April 2026
MK-677 vs Sermorelin
Sermorelin is a short-acting GHRH analog with a defined approved indication for growth hormone deficiency. MK-677 is an oral ghrelin mimetic used in research contexts.
MK-677 / Ibutamoren
GH Secretagogue
3.9/ 5
B+
Sermorelin
GH Releasing
4.1/ 5
A−
Editor's note
Sermorelin has a narrower approved-indication pathway; MK-677 is oral but research-only.
| Criterion | MK-677 / Ibutamoren | Sermorelin |
|---|---|---|
| Mechanism | Ghrelin mimetic | GHRH analog |
| Route | Oral | Subcutaneous injection |
| Half-life | Short | Very short |
| Regulatory status (AU) | Not approved | Defined indication pathway |
| GH release pattern | Sustained elevation | Physiologic pulsatile release |
Frequently asked questions
Sermorelin has a clear approved-indication pathway; MK-677 is research-only.
Want to read the full reviews?